S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
The perfect AI stock under $10 (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
The perfect AI stock under $10 (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
My wife was skeptical... until I showed her my account balance. (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
The perfect AI stock under $10 (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
The perfect AI stock under $10 (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
My wife was skeptical... until I showed her my account balance. (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
The perfect AI stock under $10 (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
The perfect AI stock under $10 (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
My wife was skeptical... until I showed her my account balance. (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
The perfect AI stock under $10 (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
The perfect AI stock under $10 (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
My wife was skeptical... until I showed her my account balance. (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage

Achilles Therapeutics (ACHL) Competitors

$1.36
0.00 (0.00%)
(As of 02/23/2024 08:52 PM ET)

ACHL vs. TARA, OKYO, GMDA, ALGS, CYTH, ESLA, DYAI, CRTX, CADL, and TSBX

Should you be buying Achilles Therapeutics stock or one of its competitors? The main competitors of Achilles Therapeutics include Protara Therapeutics (TARA), OKYO Pharma (OKYO), Gamida Cell (GMDA), Aligos Therapeutics (ALGS), Cyclo Therapeutics (CYTH), Estrella Immunopharma (ESLA), Dyadic International (DYAI), Cortexyme (CRTX), Candel Therapeutics (CADL), and Turnstone Biologics (TSBX). These companies are all part of the "medical" sector.

Achilles Therapeutics vs.

Achilles Therapeutics (NASDAQ:ACHL) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk.

Achilles Therapeutics' return on equity of -42.33% beat Protara Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Achilles TherapeuticsN/A -42.33% -37.49%
Protara Therapeutics N/A -44.17%-39.32%

Achilles Therapeutics presently has a consensus price target of $11.00, indicating a potential upside of 708.82%. Protara Therapeutics has a consensus price target of $23.00, indicating a potential upside of 446.32%. Given Achilles Therapeutics' higher possible upside, equities research analysts plainly believe Achilles Therapeutics is more favorable than Protara Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Achilles Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Protara Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Protara Therapeutics received 11 more outperform votes than Achilles Therapeutics when rated by MarketBeat users. Likewise, 60.00% of users gave Protara Therapeutics an outperform vote while only 55.17% of users gave Achilles Therapeutics an outperform vote.

CompanyUnderperformOutperform
Achilles TherapeuticsOutperform Votes
16
55.17%
Underperform Votes
13
44.83%
Protara TherapeuticsOutperform Votes
27
60.00%
Underperform Votes
18
40.00%

Achilles Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.

Achilles Therapeutics is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Achilles TherapeuticsN/AN/A-$71.18M-$1.89-0.72
Protara TherapeuticsN/AN/A-$65.95M-$6.13-0.69

In the previous week, Achilles Therapeutics had 1 more articles in the media than Protara Therapeutics. MarketBeat recorded 2 mentions for Achilles Therapeutics and 1 mentions for Protara Therapeutics. Achilles Therapeutics' average media sentiment score of 0.46 beat Protara Therapeutics' score of 0.00 indicating that Achilles Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Achilles Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Protara Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

48.4% of Achilles Therapeutics shares are owned by institutional investors. Comparatively, 46.4% of Protara Therapeutics shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by insiders. Comparatively, 18.4% of Protara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Achilles Therapeutics and Protara Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.


Get Achilles Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACHL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACHL vs. The Competition

MetricAchilles TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$55.46M$2.73B$4.82B$7.46B
Dividend YieldN/A2.35%5.40%3.86%
P/E Ratio-0.7210.02244.0318.27
Price / SalesN/A199.823,023.6968.34
Price / CashN/A21.2590.7154.77
Price / Book0.274.054.384.77
Net Income-$71.18M$73.80M$108.96M$205.13M
7 Day Performance28.30%1.54%112.79%0.64%
1 Month Performance41.67%11.45%121.55%7.69%
1 Year Performance21.43%22.23%133.39%6.22%

Achilles Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TARA
Protara Therapeutics
1.9819 of 5 stars
$3.99
-1.7%
$23.00
+476.4%
+24.6%$45.33MN/A-0.6525Gap Down
High Trading Volume
OKYO
OKYO Pharma
3.2933 of 5 stars
$1.45
+2.8%
$5.00
+244.8%
-28.8%$41.80MN/A0.008Gap Down
GMDA
Gamida Cell
1.7062 of 5 stars
$0.39
-4.9%
$5.40
+1,288.2%
-75.9%$41.08MN/A-1.30143
ALGS
Aligos Therapeutics
2.5501 of 5 stars
$0.64
-1.5%
N/A-51.9%$47.98M$13.91M-0.3468Gap Up
CYTH
Cyclo Therapeutics
1.8658 of 5 stars
$1.75
-0.6%
$4.00
+128.6%
+62.0%$39.78M$1.38M-1.059Positive News
ESLA
Estrella Immunopharma
0 of 5 stars
$1.06
-3.6%
N/AN/A$38.81MN/A0.00N/APositive News
DYAI
Dyadic International
1.8277 of 5 stars
$1.34
+1.5%
$6.00
+347.8%
+10.4%$38.61M$2.93M-5.837Positive News
CRTX
Cortexyme
0 of 5 stars
$1.28
-1.5%
N/A+39.8%$38.59MN/A-0.4355
CADL
Candel Therapeutics
3.0537 of 5 stars
$1.72
flat
$9.00
+423.3%
-10.7%$49.74M$120,000.00-1.5676Gap Down
TSBX
Turnstone Biologics
1.8802 of 5 stars
$2.27
-11.7%
$19.00
+737.0%
N/A$52.42M$29.75M0.0094Upcoming Earnings

Related Companies and Tools

This page (NASDAQ:ACHL) was last updated on 2/26/2024 by MarketBeat.com Staff